Navigation Links
VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Date:5/4/2008

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN.OB), a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen $2 million upon execution of the definitive agreement and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

"We have marketed our anthrax vaccine candidate and related technology very broadly over the last 12 months," said James P. Panek, VaxGen President and CEO. "In Emergent, we believe we have identified a partner whose expertise in the field and track record in contracting with government agencies maximizes the chances of returns for our shareholders."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the potential receipt of milestone payments and specified percentages of future net sales from Emergent BioSolutions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen and Raven Terminate Merger Agreement
2. VaxGen Issues Rebuttal to MedCap Letter
3. VaxGen Common Stock Now Quoted on OTC Bulletin Board
4. VaxGen Reports Financial Update
5. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
6. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
7. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
8. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
9. VaxGen Addresses MPM Claims in Letter to Stockholders
10. VaxGen Files Last Outstanding Periodic Report With SEC
11. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... MA (PRWEB) , ... December 09, 2016 , ... Aditya ... that in addition to Australia, Europe, and the United States, Axiomed is now gaining ... assure interest in this technology." , Mr. Humad went on to say that, “We ...
(Date:12/9/2016)... India , December 9, 2016 According ... & Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, ... Forecasts to 2021" published by MarketsandMarkets, the global market is expected ... in 2016, at a CAGR of 10.6% during the forecast period. ... ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable ... is taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators ... the playing field at a Smart Talk session. Smart Talk will run from ...
(Date:12/8/2016)... and CARDIFF, UK (PRWEB) , ... December 08, ... ... very high precision light to control cells — optogenetics — is key to ... current state of the art, spatially patterned light projected via free-space optics stimulates ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
Breaking Biology News(10 mins):